Research

Hormonal

Pharmacological inhibition of DPP-4 improves glycemic control in Type 2 Diabetes by preventing the degradation of endogenous incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon.

DPP-4 inhibitors (like vildagliptin, sitagliptin) are oral medications that help your body manage blood sugar more effectively by keeping your natural 'incretin' hormones (GLP-1 and GIP) active longer. They are safe, well-tolerated, and do not typically cause low blood sugar on their own. They work best when your blood sugar is high, stimulating insulin only when needed.

StrongSupportsVERY_HIGH confidence
DPP-4 inhibition was proposed as a novel approach to the treatment of T2DM... DPP-4 inhibitors are now an established therapy of T2DM... DPP-4 inhibition was well-tolerated in humans and was associated with significantly lower fasting and meal-related glucose concentrations.
Carolyn F. Deacon · Frontiers in Endocrinology · 2019

Why this rating

Supported by multiple Phase 2/3 clinical trials, long-term efficacy studies, and regulatory approval.

Source

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Carolyn F. Deacon · Frontiers in Endocrinology · 2019

DOI 10.3389/fendo.2019.00080

narrative_reviewCited 416×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →